M&A, Recapitalization, and Growth Financing Advice to Drive Transformative Transactions

Crosstree serves as your vested partner to empower you — a founder, investor, or operator — to confidently connect with leading health science companies, align interests, and optimize outcomes. Working within the pharma services, diagnostics and tools, and digital health sectors, Crosstree identifies transformational trends and helps clients explore greater market insights and financial possibilities by providing objective insight to deliver the best possible outcome.

WHERE SUPERIOR OUTCOMES ARE THE STANDARD

90%

Success Rate

85%

Strategic Buyers

35%

Cross-border

See the Results

Crosstree’s Client Outcomes Consistently Exceed Industry Benchmarks

Crosstree’s deep industry focus fosters efficient project execution. The company’s relationships with investors and strategic buyers are unmatched in the industry.

Crosstree’s deals consistently achieve “spike valuations” through concise articulation of client value propositions, credible financial and technical support, and thoughtful alignment of industry trends.

Crosstree’s culmination of industry expertise that leverages market data, trends, and a high-profile network, drives an outstanding closing rate of almost 90%.

By combining technology, structured project management methodology, and a focused process approach, Crosstree closes transactions faster — with less resourcing strain on clients — compared to traditional investment banks.

We were impressed with the intensity and thoroughness of Crosstree’s preparation. Their team worked tirelessly on analytics and positioning, ultimately giving us the flexibility to efficiently navigate various strategic options involving our business and each of its two divisions. I wouldn’t think twice about using Crosstree again.

Crosstree did an exceptional job with our process. We benefited greatly from their industry knowledge, expansive network, deal expertise and just plain hard work. Most importantly, their bankers demonstrated sterling integrity and always gave us sound advice that resulted in an excellent outcome, despite numerous twists and turns along the way.

Crosstree’s specific knowledge of our market segment allowed them to precisely target potential buyers. Further, Crosstree guided management to the right “value drivers” for each potential buyer, optimally tuning our various presentations, and ultimately driving enhanced valuations during the auction process.

Recent Deals

Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally